ArticleACS omega2020
Developing Biodegradable Nanoparticles Loaded with Mometasone Furoate for Potential Nasal Drug Delivery.
Article in ACS omega, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 48 citations in OpenAlex.
- Article
- Nanoparticle-Based Targeted Drug Delivery Systems for Allergic Rhinitis: A Comprehensive Review.International journal of nanomedicine · 2026Review
- The effectiveness of hydrogel matrix containing nitric oxide, silver nanoparticles, vancomycin, and ciprofloxacin on methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa biofilm isolated from patients with chronic rhinosinusitis.European journal of medical research · 2025Article
- pH-responsive release of small molecule pharmaceuticals from a reworked adsorbent hydrogel for environmental applications.RSC advances · 2025Article
- Advancements in nasal drug delivery system of natural products.Frontiers in pharmacology · 2025Review
- Multilayer Nanocarrier for the Codelivery of Interferons: A Promising Strategy for Biocompatible and Long-Acting Antiviral Treatment.Pharmaceutics · 2024Article
- Sustained co-release of ciprofloxacin and dexamethasone in rabbit maxillary sinus using polyvinyl alcohol-based hydrogel microparticle.Journal of materials science. Materials in medicine · 2024Article
- Glutathione and bicarbonate nanoparticles improve mucociliary transport in cystic fibrosis epithelia.International forum of allergy & rhinology · 2024Article
- Chitosan nanoparticles improve the effectivity of miltefosine against Acanthamoeba.PLoS neglected tropical diseases · 2024Article
- Zein nanoparticles as oral carrier for mometasone furoate delivery.Drug delivery and translational research · 2023Article
- Article
- Rapidly Dissolving Microneedles for the Delivery of Steroid-Loaded Nanoparticles Intended for the Treatment of Inflammatory Skin Diseases.Pharmaceutics · 2023Article
- A Supine Position and Dual-Dose Applications Enhance Spray Dosing to the Posterior Nose: Paving the Way for Mucosal Immunization.Pharmaceutics · 2023Article
- PLGA-Based Nanomedicine: History of Advancement and Development in Clinical Applications of Multiple Diseases.Pharmaceutics · 2022Review
- Designing of SiOFrontiers in cell and developmental biology · 2022Article
- Nasal therapy-The missing link in optimising strategies to improve prevention and treatment of COVID-19.PLoS pathogens · 2021Article
- Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2.Journal of controlled release : official journal of the Controlled Release Society · 2021Review
- A thermoresponsive hydrogel system for long-acting corticosteroid delivery into the paranasal sinuses.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- Current Perspective on Nasal Delivery Systems for Chronic Rhinosinusitis.Pharmaceutics · 2021Review
- Poly(anhydride-ester) gemcitabine: Synthesis and particle engineering of a high payload hydrolysable polymeric drug for cancer therapy.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intranasal drug administration is considered a routine in the treatment of many nasal conditions including chronic rhinosinusitis (CRS), which is a common disease involving long-term inflammation of the nasal mucosa. Topical nasal steroid treatment is safe and easy to use and plays a basic role in both nonsurgical and surgical treatments for CRS. Intranasal steroid therapy for various time intervals is commonly used before and after endoscopic CRS nasal surgeries to reduce inflammation and edema and to improve mucosal healing. The medication is currently administered via conventional nasal sprays; therefore, there is an incentive to develop more efficient drug delivery systems for the controlled release of topical steroids into the sinonasal cavities over a prolonged period of time. In this study, poly(lactic-
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.